Effect Of Sacubitril/valsartan On Heart Failure With Preserved Ejection Fraction

Objective To analyze and explore the effect of sacubitril valsartan on heart failure with preserved ejection fraction,and to provide clinical basis for its treatment.Methods A total of 100 patients with heart failure with preserved ejection fraction who were treated in General Hospital of Ningxia Medical University from July 2019 to September2020 were selected and divided into conventional treatment group and sacubitril valsartan treatment group according to random number table method,with 50 patients in each group.The control group was given conventional anti-heart failure treatment,and the observation group was given sacubitril valsartan on the basis of conventional treatment,the treatment period was 3 months.The systolic blood pressure,heart rate,serum creatinine,serum potassium,Aspartate amino transferase(AST),Alanine amino transferase(ALT)and cardiac function indexes(including NT-pro BNP level,left ventricular ejection fraction,left ventricular end-systolic diameter,left ventricular end-diastolic diameter,left ventricular end-systolic volume,and left ventricular end-diastolic volume),before and after treatment were compared between the two groups.cardiovascular adverse events were observed during treatment,and drug-related adverse reactions were recorded during treatment.Results A total of 100 patients with heart failure with preserved ejection fraction were included in this study.Among them,the control group: 39 males and 11 females,the ratio of male to female is 3.55:1,and the average age is 63.38 ±5.11 years old;There were 36 patients with hypertension(72.00%),35 patients with coronary heart disease(70.00%),19 patients with diabetes mellitus(38.00%)and 10 patients with atrial fibrillation(20.00%).Observation group: there were 37 males and 13 females,the ratio of male to female was 2.85:1,and the average age was 64.82 ±5.00 years.There were 39 patients with hypertension(78.00%),36 patients with coronary heart disease(72.00%),20 patients with diabetes mellitus(40.00%)and 9 patients with atrial fibrillation(18.00%).There is no statistical difference in baseline data between the two groups before treatment.after treatment,the left ventricular ejection fraction(LVEF),left ventricular end systolic diameter(LVESD),left ventricular end diastolic diameter(LVEDD),left ventricular end systolic volume(LVESV)and left ventricular end diastolic volume(LVEDV)were improved,and LVEF in observation group was higher than that in control group,while LVESD,LVEDD and LVESV were lower than that in control group(P<0.05).Compared with the same group before treatment,the level of N-terminalpro-BNP(NT-pro BNP)decreased in both groups after treatment,and the decrease in the observation group was more obvious than that in the control group(P<0.05).The effective rate of improving cardiac function in the observation group was 90.00%,which was higher than that in the control group 76.00%,and the difference was statistically significant(P<0.05).Compared with the control group,there was no significant difference in the incidence of cardiovascular adverse events in the observation group(P=0.05).Compared with the control group,the incidence of adverse reactions in the observation group had no statistical significance(P>0.05).Conclusion 1.Compared with conventional antiheart failure drugs,the addition of sacubitril valsartan can significantly improve the cardiac function of patients with heart failure preserved by ejection fraction.2.Sacubitril valsartan can improve the clinical efficacy and is safe without increasing the incidence of adverse reactions.